In this podcast, Motley Fool analysts Nick Sciple and Karl Theil join hosts Ricky Mulvey and Mary Long to discuss: Kroger 's business results. Why some investors are becoming more pessimistic about ...

The latest HPRA inspection in February 2025 was highly successful-both QC licences were renewed, and viral vector manufacturing was added to the MIA (IMP) licence. This means the Shannon site can ...

AI can help with workload distributions when considering on-device versus cloud processing. The latter has a very large ...

Photonic neuromorphic systems use light for high-speed computation, surpassing traditional electronics and driving innovations in AI and image processing.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

While losing weight can be difficult, wearable technologies like watches and rings can make the journey a lot more pleasant.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...

The challenge of the obesity epidemic is widespread and one that even pediatricians face constantly,” a Connecticut doctor ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo ...